A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

BACKGROUND: Ustekinumab (UST), a monoclonal antibody to IL-12 and 23, was recently approved for the treatment of moderate-severe CD. AIMS: Here we report safety data with and without concomitant use of Immunomodulators(IMM) and corticosteroids(CS) in induction and maintenance in pts pooled from the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Can Assoc Gastroenterol
Main Authors: Sands, B E, Gasink, C, Jacobstein, D, Ott, E, Lang, Y, Ramachandran, P, Ghosh, S
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Paper Sessions
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508235/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.106
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki